No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Mark S. Sulkowski, Wan Long Chuang, Jia Horng Kao, Jenny C. Yang, Bing Gao, Diana M. Brainard, Kwang Hyub Han, Edward Gane

Research output: Contribution to journalArticle

42 Citations (Scopus)


Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.

Original languageEnglish
Pages (from-to)1202-1204
Number of pages3
JournalClinical Infectious Diseases
Issue number9
Publication statusPublished - 2016 Nov 1


All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this